Literature DB >> 15034192

Hexosamines are unlikely to function as a nutrient-sensor in 3T3-L1 adipocytes: a comparison of UDP-hexosamine levels after increased glucose flux and glucosamine treatment.

Remko R Bosch1, Marie-José J M Pouwels, Paul N Span, André J Olthaar, Cees J Tack, Ad R M M Hermus, C G J Sweep.   

Abstract

Whether the hexosamine biosynthesis pathway acts as a nutrient-sensing pathway is still unclear. Glucose is directed into this pathway by GFAT. Because the activity of GFAT is tightly regulated, we examined whether UDP-hexosamine levels can increase significantly and dose-dependently in response to elevated glucose concentrations. In glucosamine-treated 3T3-L1 adipocytes, inhibition of insulin-stimulated glucose uptake was highly correlated with UDP-hexosamine levels (r = -0.992; p < 0.0001 for UDP-GlcNAc and r = -0.996; p < 0.0001 for UDP-GalNAc). Incubation of 3T3-L1 adipocytes with 0.1 microM insulin for 24 h in medium containing 1 and 5 mM glucose increased the rate of glucose uptake by 365% and 175% compared to untreated cells, respectively. This increase was not observed when the cells were incubated for 24 h with insulin in medium containing 10 or 25 mM glucose. However, treatment of cells with insulin and 1, 5, 10, or 25 mM glucose resulted in similar increases in levels of UDP-GlcNAc and UDP-GalNAc that always amounted to approx 30-40% above baseline values. This led us to conclude that despite exposure of adipocytes to conditions of extreme and prolonged glucose disposal, the increases in cellular UDP-hexosamines were minimal and not dependent on the extracellular glucose concentration. Taken together, our results are in line with the hypothesis that in glucosamine-treated adipocytes UDP-hexosamines influence insulin-stimulated glucose uptake. However, our observations in glucose-treated adipocytes argue against the possibility that UDP-hexosamines function as a nutrient-sensor, and question the role of the hexosamine biosynthesis pathway in the pathogenesis of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034192     DOI: 10.1385/endo:23:1:17

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Assay for hexosamine pathway intermediates (uridine diphosphate-N-acetyl amino sugars) in small samples of human muscle tissue.

Authors:  P N Span; M J Pouwels; A J Olthaar; R R Bosch; A R Hermus; C G Sweep
Journal:  Clin Chem       Date:  2001-05       Impact factor: 8.327

2.  Overexpression of glutamine:fructose-6-phosphate amidotransferase in rat-1 fibroblasts enhances glucose-mediated glycogen accumulation via suppression of glycogen phosphorylase activity.

Authors:  E D Crook; G Crenshaw; G Veerababu; L P Singh
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

3.  Glucosamine-induced insulin resistance in 3T3-L1 adipocytes.

Authors:  E Heart; W S Choi; C K Sung
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-01       Impact factor: 4.310

4.  Increased hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal.

Authors:  M Hawkins; N Barzilai; W Chen; I Angelov; M Hu; P Cohen; L Rossetti
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

5.  Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance.

Authors:  L F Hebert; M C Daniels; J Zhou; E D Crook; R L Turner; S T Simmons; J L Neidigh; J S Zhu; A D Baron; D A McClain
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues.

Authors:  A Virkamäki; M C Daniels; S Hämäläinen; T Utriainen; D McClain; H Yki-Järvinen
Journal:  Endocrinology       Date:  1997-06       Impact factor: 4.736

7.  Short-term glucosamine infusion does not affect insulin sensitivity in humans.

Authors:  M J Pouwels; J R Jacobs; P N Span; J A Lutterman; P Smits; C J Tack
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes.

Authors:  B A Nelson; K A Robinson; M G Buse
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

9.  Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor.

Authors:  K A Robinson; D A Sens; M G Buse
Journal:  Diabetes       Date:  1993-09       Impact factor: 9.461

10.  Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase.

Authors:  G L McKnight; S L Mudri; S L Mathewes; R R Traxinger; S Marshall; P O Sheppard; P J O'Hara
Journal:  J Biol Chem       Date:  1992-12-15       Impact factor: 5.157

View more
  5 in total

Review 1.  O-GlcNAc signaling: a metabolic link between diabetes and cancer?

Authors:  C Slawson; R J Copeland; G W Hart
Journal:  Trends Biochem Sci       Date:  2010-05-11       Impact factor: 13.807

2.  Hyperglycemia-induced O-GlcNAcylation and truncation of 4E-BP1 protein in liver of a mouse model of type 1 diabetes.

Authors:  Michael D Dennis; Tabitha L Schrufer; Sarah K Bronson; Scot R Kimball; Leonard S Jefferson
Journal:  J Biol Chem       Date:  2011-08-12       Impact factor: 5.157

3.  UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation.

Authors:  H M Itkonen; N Engedal; E Babaie; M Luhr; I J Guldvik; S Minner; J Hohloch; M C Tsourlakis; T Schlomm; I G Mills
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 9.867

Review 4.  O-GlcNAc cycling in the developing, adult and geriatric brain.

Authors:  Olof Lagerlöf
Journal:  J Bioenerg Biomembr       Date:  2018-05-22       Impact factor: 2.945

Review 5.  O-GlcNAcylation and its role in the immune system.

Authors:  Yi-Hsuan Chang; Chia-Lin Weng; Kuo-I Lin
Journal:  J Biomed Sci       Date:  2020-04-29       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.